Daily Respiratory Research Analysis
Analyzed 58 papers and selected 3 impactful papers.
Summary
Analyzed 58 papers and selected 3 impactful articles.
Selected Articles
1. Multicohort analysis unveils axon guidance pathways linking small for gestational age to spirometric restriction.
Across multiple birth cohorts, ~one-third of SGA children showed a cord-blood proteomic endotype characterized by dysregulated axon-guidance proteins; these proteins were inversely associated with later-life spirometric indices. Convergent evidence from GWAS and a sheep model linked axon-guidance genes to restrictive ventilatory patterns, suggesting a developmental molecular pathway from fetal growth restriction to adult lung function.
Impact: This work uncovers a mechanistic bridge between fetal growth restriction and later restrictive ventilatory defects through axon-guidance biology, integrating human multi-omics with animal validation.
Clinical Implications: Findings support early-life risk stratification and surveillance for children born SGA, and nominate axon-guidance proteins as biomarkers and potential targets for preventive strategies against later restrictive lung disease.
Key Findings
- Approximately one-third of SGA children exhibited a cord-blood endotype with dysregulated axon-guidance proteins.
- Later-life peripheral blood levels of these proteins were inversely associated with spirometric restriction.
- GWAS and an experimental sheep model provided convergent evidence linking axon-guidance genes to spirometric indices.
Methodological Strengths
- Multicohort human proteomic analysis spanning birth and later-life assessments
- Cross-validation using GWAS and an independent large-animal (sheep) experimental model
Limitations
- Observational design limits causal inference despite supportive MR/animal data
- Cohort heterogeneity and incomplete details on sample sizes and effect magnitudes in the abstract
Future Directions: Validate endotypes across ancestries, develop clinically deployable biomarker panels, and test early-life interventions targeting axon-guidance pathways to preserve lung growth and function.
Children born small for gestational age (SGA) face elevated risks of metabolic, cardiovascular, respiratory, and neurodevelopmental disorders, as well as premature mortality, yet the underlying mechanisms remain only partly understood. We analyze blood proteomic data from multiple birth cohorts to identify molecular pathways linked to SGA and to later-life lung function. We find that approximately one-third of SGA children exhibit a distinct molecular endotype marked by dysregulation of axon-guidance proteins in cord blood. In peripheral blood collected later in life, these proteins are inversely associated with contemporaneous spirometric restriction. Using GWAS data and an experimental sheep model, we obtain convergent evidence that axon-guidance genes are associated with spirometric indices (FEV
2. A dynamic proteomic signature for the prediction of lung Cancer: a longitudinal analysis in the UK Biobank cohort.
In 37,759 UK Biobank participants (342 incident cases), 340 proteins showed time-dependent associations with lung cancer, resolving into four trajectory patterns spanning >5 years pre-diagnosis to imminent risk. An integrated 28-protein plasma signature with clinical factors and PRS achieved an AUC of 0.830, and Mendelian randomization suggested causal roles for selected proteins.
Impact: This study delineates a molecular timeline of lung carcinogenesis and delivers a high-performing, trajectory-aware proteomic signature for pre-diagnostic risk prediction.
Clinical Implications: The 28-protein signature could augment current risk models to prioritize low-dose CT screening, enable earlier detection, and guide precision prevention, pending external and prospective validation.
Key Findings
- Identified 340 risk-associated proteins with distinct temporal heterogeneity relative to diagnosis.
- Four trajectory patterns separated long-term (>5 years) and imminent (<5 years) risk biology (e.g., CEACAM5 vs. IL-6).
- A 28-protein signature plus clinical factors and PRS achieved AUC 0.830; MR suggested causal roles for selected proteins.
Methodological Strengths
- Large prospective cohort with long median follow-up and rich proteomic profiling
- Multi-method pipeline (time-stratified Cox, LOESS trajectories, ML, Mendelian randomization)
Limitations
- External validation cohorts and clinical utility studies are needed to confirm generalizability and real-world impact
- Potential residual confounding and overfitting despite model regularization and internal validation
Future Directions: Prospective external validation, calibration for diverse populations, health-economic evaluation for screening pathways, and interventional studies targeting causal proteins.
BACKGROUND: To understand the molecularly obscure pre-diagnostic phase of lung cancer, we mapped the temporal evolution of the plasma proteome for new biological insights and improved risk prediction. METHODS: Leveraging the UK Biobank prospective cohort, we analyzed 2,921 plasma proteins from 37,759 participants, including 342 incident lung cancer cases identified over a median follow-up of 11.7 years. We employed time-stratified Cox models, locally weighted scatterplot smoothing (LOESS) trajectory modeling, and hierarchical clustering to characterize protein dynamics relative to the time of diagnosis. A multi-algorithm machine learning pipeline was used to develop a predictive signature, and two-sample Mendelian randomization was performed to infer causal relationships. RESULTS: We identified 340 risk-associated proteins showing significant temporal heterogeneity. Long-term risk (>5 years pre-diagnosis) was linked to proteins like CEACAM5, indicating early dysregulation of cell adhesion. Imminent risk (<5 years) was marked by a surge in inflammatory proteins like IL6. These dynamics were resolved into four distinct trajectory patterns, creating a molecular timeline of carcinogenesis. A machine learning-derived 28-protein signature, integrated with clinical factors and Polygenic Risk Score (PRS), achieved outstanding predictive performance (AUC = 0.830). Mendelian randomization also suggested a causal role for some proteins of 340 risk-associated proteins in lung cancer development. CONCLUSION: Our findings establish that lung cancer evolves through a dynamic sequence of protein changes. This provides a new model for understanding pre-diagnostic disease, and our 28-protein signature is a powerful tool for precision screening to identify individuals with active disease progression.
3. Lipid nanoparticle-encapsulated DNA vaccine prevented lung consolidation following heterologous influenza A virus challenge in pigs.
Under heterologous IAV challenge in pigs, neither HA protein nor HA DNA vaccines induced cross-HI antibodies or prevented nasal shedding. The protein vaccine exacerbated lung lesions (VAERD-like), whereas the LNP-DNA HA vaccine prevented gross lung pathology and showed distinct transcriptomic responses, indicating a safer vaccination platform under antigenic mismatch.
Impact: Addresses the critical safety issue of VAERD under antigenic mismatch and demonstrates that an LNP-DNA HA vaccine can avoid enhanced lung pathology, informing rational vaccine design.
Clinical Implications: For veterinary medicine, LNP-DNA platforms may reduce severe respiratory pathology during mismatch outbreaks. Translationally, the findings guide human vaccine strategies to mitigate mismatch-related enhanced disease risk.
Key Findings
- Neither HA protein nor HA DNA vaccines induced cross-reactive HI antibodies or prevented nasal viral shedding under heterologous challenge.
- HA protein vaccination exacerbated lung consolidation compared with non-vaccinated controls, while LNP-DNA HA vaccination prevented gross lung pathology.
- Transcriptomic profiling demonstrated distinct gene expression programs between vaccine modalities.
Methodological Strengths
- Relevant large-animal (swine) heterologous challenge model reflecting field antigenic mismatch
- Head-to-head platform comparison with pathology and transcriptomic endpoints
Limitations
- Sample size and detailed immunophenotyping (e.g., T-cell cross-reactivity) are not described in the abstract
- Translatability to humans requires caution and dedicated clinical studies
Future Directions: Quantify cellular cross-immunity, define correlates of protection without VAERD, optimize dosing/schedules, and evaluate platform safety across diverse IAV lineages.
The substantial antigenic diversity of Influenza A virus (IAV) presents significant challenges to the development of broadly protective vaccines for swine. Moreover, pigs vaccinated with whole-inactivated virus or hemagglutinin (HA) subunit vaccines may experience more severe lung consolidation than non-vaccinated pigs when exposed to antigenically mismatched IAV strains, a phenomenon known as vaccine-associated enhanced respiratory disease (VAERD). We recently developed a lipid nanoparticle-encapsulated DNA (LNP-DNA) vaccine encoding the HA of IAV, which elicited robust immune responses following a single immunization and protected pigs against homologous IAV challenges. In this study, we compared the immunogenicity and protective efficacy between the HA protein-based vaccine and the HA DNA-based vaccine against an antigenically mismatched IAV strain in pigs. Neither vaccine induced cross-reactive hemagglutination inhibition (HI) antibodies nor prevented viral shedding in nasal secretions following heterologous challenge. However, while the HA protein-based vaccine exacerbated lung lesions compared to non-vaccinated controls, the HA DNA-based vaccine prevented the development of gross lung pathology. Transcriptomic analyses revealed distinct gene expression profiles between the two vaccine groups. These findings suggest that the LNP-DNA vaccine platform may offer a safer and more effective strategy for developing vaccines against IAV in swine.